The estimated Net Worth of Catherine J Mackey is at least $383 Mille dollars as of 14 December 2023. Catherine Mackey owns over 9,612 units of GW Pharmaceuticals stock worth over $1,164 and over the last 6 years he sold GWPH stock worth over $24,440. In addition, he makes $357,823 as Non-Executive Independent Director at GW Pharmaceuticals.
Sign up
Catherine Mackey GWPH stock SEC Form 4 insiders trading
Catherine has made over 8 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 9,612 units of GWPH stock worth $673 on 14 December 2023.
The largest trade he's ever made was exercising 9,612 units of GW Pharmaceuticals stock on 14 December 2023 worth over $673. On average, Catherine trades about 1,147 units every 69 days since 2019. As of 14 December 2023 he still owns at least 16,623 units of GW Pharmaceuticals stock.
You can see the complete history of Catherine Mackey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Catherine Mackey biography
Dr. Catherine J. Mackey Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Mackey is an experienced corporate executive, director and advisor with over 30 years of accomplishment in the biotechnology, pharmaceutical, and agricultural industries. She is chairman of the board of Cour Pharmaceutical Development, a privately held, clinical stage company focused on immunomodulation. She is also a member of the board of directors of Poseida, a privately held, clinical stage company developing next generation cell therapies for cancer. Dr. Mackey served as a member of the board of directors and the compensation committee of YM Biosciences Inc., a Canadian drug development company, from 2011 to 2013. She also served as a member of the board of directors, the audit committee, and nominating and corporate governance committee of Sequenom Inc., a life sciences company, from 2015 to 2016. In addition, she serves on the board of directors of Rady Children’s Hospital and as an advisor to several companies. Dr. Mackey previously served as senior vice president of Pfizer Worldwide R&D and director of Pfizer’s La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer’s main pharmaceutical research and development sites with over 1,000 employees and a robust drug pipeline. Prior to that role, she served as head of Strategic Alliances and Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as vice president of DEKALB Genetics, Inc., an international researcher, producer, and marketer of seed. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University.
What is the salary of Catherine Mackey?
As the Non-Executive Independent Director of GW Pharmaceuticals, the total compensation of Catherine Mackey at GW Pharmaceuticals is $357,823. There are 9 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is Catherine Mackey?
Catherine Mackey is 64, he's been the Non-Executive Independent Director of GW Pharmaceuticals since 2017. There are 2 older and 10 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Catherine Mackey's mailing address?
Catherine's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble e Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Catherine Mackey stock trades at GW Pharmaceuticals, Trillium Therapeutics Inc, Voyager Therapeutics Inc, Avid Bioservices Inc, Avid Bioservices Inc, IDEAYA Biosciences e Poseida Therapeutics
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America